Capricor Therapeutics Stock Climbs on Deramiocel Regulatory Updates

By EC Assets · Published 1 September 2026

Capricor Therapeutics Inc. stock is rising following updates regarding its therapeutic deramiocel. The biotechnology company develops cell and exosome-based therapeutics. Its pipeline includes CAP-1002, engineered exosomes, CAP-2003, and exosome-based vaccines. These therapies target Duchenne muscular dystrophy and other rare conditions. Capricor Therapeutics stock closed 58% higher at $6.65 on August 14. This increase occurred after the company stated the FDA was prepared to review an amendment. This amendment contains 24-month data for deramiocel. The stock also jumped 75% on separate FDA discussions concerning deramiocel for Duchenne cardiomyopathy. Capricor Therapeutics provided a regulatory update on the deramiocel Biologics License Application (BLA) in January 2026. This update followed the FDA's review of HOPE-3 topline data. Deramiocel is a key part of the company's focus. The FDA's willingness to review new data is a significant development for Capricor's BLA process. Capricor Therapeutics, a company headquartered in San Diego, is focused on rare disease treatments. The market will monitor further regulatory communications from the FDA regarding deramiocel. Investors will also look for any additional data disclosures from Capricor Therapeutics. This article is intended for informational purposes only. It does not constitute investment advice.